Global Pharmaceutical Giant Licenses LabVantage’s Sapphire™ Biobanking Solution To Support Its Biorepository Operations

LabVantage today announced that a global pharmaceutical giant has licensed LabVantage’s Sapphire Biobanking Solution to support its biorepository operations. At the heart of its research and development (R&D) efforts, its biorepositories face the challenge of managing the exponential growth of biomaterials, the expanding geography of storage locations, and the mounting complexity of internal and regulatory compliance restrictions. Its pathology and cell bank groups could no longer be managed through its existing method of Excel spreadsheets and multiple in-house developed solutions.

"The company needed an integrated, robust informatics solution specially designed for biorepository management," explained Ron Kasner, Vice President of Corporate Development at LabVantage. "Specifically, it required comprehensive data capture, location management, and compliance capabilities to help them store, locate, and access vital biospecimen information," he added. Sapphire will serve as a core technology infrastructure for their pathology and cell bank groups to track tumors, cell lines, and other derivatives through the quality control process and maintain a biorepository bank for users to search and locate required specimens for various R&D projects.

"We are proud that Sapphire will play a vital role in advancing this renowned pharmaceutical giant’s research efforts and accelerating its development of promising new products," said Jim Aurelio, CEO & President of LabVantage, "As the volume and complexity of specimen collections continuously increases around the world, this is a real case study of how pharmaceutical companies can rely on LabVantage to deliver them a tailored biobanking solution, leveraging the best combination of functionality, flexibility, and technology."